> Skip to content
FEATURED:
  • Student-Success Resource Center
Sign In
  • News
  • Advice
  • The Review
  • Data
  • Current Issue
  • Virtual Events
  • Store
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
  • Jobs
    • Find a Job
    • Post a Job
    • Career Resources
    • Find a Job
    • Post a Job
    • Career Resources
Sign In
  • News
  • Advice
  • The Review
  • Data
  • Current Issue
  • Virtual Events
  • Store
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
  • Jobs
    • Find a Job
    • Post a Job
    • Career Resources
    • Find a Job
    • Post a Job
    • Career Resources
  • News
  • Advice
  • The Review
  • Data
  • Current Issue
  • Virtual Events
  • Store
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
  • Jobs
    • Find a Job
    • Post a Job
    • Career Resources
    • Find a Job
    • Post a Job
    • Career Resources
Sign In
ADVERTISEMENT
Blog Logo

Percolator

Research that matters.

  • Twitter
  • LinkedIn
  • Show more sharing options
Share
  • Twitter
  • LinkedIn
  • Facebook
  • Email
  • Copy Link URLCopied!
  • Print

Does Ecstasy Really Cause Brain Damage?

By  Tom Bartlett
January 2, 2012

A new study published in the Archives of General Psychiatry trumpeting the dangers of Ecstasy use received a lot of attention recently. Its findings were in direct contrast to a large study released earlier last year that reached the opposite conclusion.

We're sorry. Something went wrong.

We are unable to fully display the content of this page.

The most likely cause of this is a content blocker on your computer or network.

Please allow access to our site, and then refresh this page. You may then be asked to log in, create an account if you don't already have one, or subscribe.

If you continue to experience issues, please contact us at 202-466-1032 or help@chronicle.com

A new study published in the Archives of General Psychiatry trumpeting the dangers of Ecstasy use received a lot of attention recently. Its findings were in direct contrast to a large study released earlier last year that reached the opposite conclusion.

To help sort this out, I lobbed a few questions at Brad Burge of the Multidisciplinary Association for Psychedelic Studies:

Q. Your group financially supports MDMA research and also hopes to get FDA approval for the drug as a prescription treatment. One of the authors of this new paper says their findings provide the “strongest evidence to date that the drug causes chronic loss of serotonin in humans.” What do you say to that?

A. In fact there is nothing new to this claim. Government-funded researchers have been making these claims ever since the media started reporting on recreational Ecstasy use in the early 1980s. Most researchers, including the authors of this study, fail to ask or answer a number of important questions: (1) Were the users they observed only taking Ecstasy, or were they taking other drugs at the same time (e.g. cocaine, alcohol, caffeine, etc.)? (2) Ecstasy is not the same as MDMA—did the drugs these women take actually contain MDMA, or contain MDMA in addition to other substances? (3) How much were they really taking? (4) Since this was an observational study, causal statements such as these should not be made.

Q. “Government-funded researchers” is a bit of a dismissive phrase. Lots of researchers are supported by funding from federal agencies. Is the implication here that, when it comes to MDMA, research financed by the government is not credible?

ADVERTISEMENT

A. It would be more to the point to say that when it comes to MDMA, much research funded by the government has not been credible. Lots of studies, including Cowan’s [Ronald Cowan of Vanderbilt University is the study’s co-author], have been methodologically flawed concerning polydrug use, unknown contents of black-market Ecstasy, and quantity of use.

Even worse, media have distorted the results to make huge, fear-based claims. There is no connection between Cowan’s study results and the associated claim that “Ecstasy causes permanent brain damage.” There are big differences between two years and forever, between changed serotonin levels and brain damage, between Ecstasy and MDMA, and between recreational and clinical use.

Studies have to be designed carefully enough that they actually measure what they claim to be measuring, and their results have to be reported responsibly.

Q. You’re certainly right that headlines overstated the case (for instance: “Ecstasy Causes Long-Term Brain Damage”). But in interviews, Cowan cautioned against assuming causation and pointed out that there’s “a difference between using the drug recreationally and using it therapeutically, at a low dose in a controlled setting.” So is this really a case of a biased study, or is it just—as you put it—irresponsible news reporting? Researchers aren’t responsible for bad headlines, right?

A. Right, as long as they carefully qualify their results and don’t leap to conclusions. Cowan’s statements and qualifications are definitely reasonable.

ADVERTISEMENT

Irresponsible reporting of scientific results can cause real harm. Sensational headlines evoke fear, which makes it harder for people to accept research results in a rational, unbiased way.

Q. What’s the next step for MDMA research?

A. Increasingly, researchers and regulators alike are starting to take the science of MDMA at face value. Rather than ignore results or push their own agenda, a fast-growing field of researchers is studying MDMA from a clinical perspective.

We’re now in the midst of Phase 2 clinical trials of MDMA-assisted psychotherapy for posttraumatic stress disorder, and we’re showing that in the right circumstances and with the appropriate preparation MDMA can be a profoundly effective therapeutic tool. We are also offering a $10,000 grant to a team of researchers who can develop a protocol for MDMA therapy as a treatment for autism spectrum disorders.

We’re not a policy organization, we’re a research organization. We don’t lobby to change laws, but we do recognize that the research we do has a context. Part of that context is the war on drugs. When research shows, as it has, that it is possible to use MDMA, other psychedelics, and marijuana in safe and responsible ways, that undermines the logic of the war on drugs that blindly assumes that these substances can only be harmful. The fate of psychedelic research may very well depend on the quality of the public education—and journalistic coverage—that surrounds it.

Tom Bartlett
Tom Bartlett is a senior writer who covers science and ideas. Follow him on Twitter @tebartl.
ADVERTISEMENT
ADVERTISEMENT
  • Explore Content
    • Latest News
    • Newsletters
    • Letters
    • Free Reports and Guides
    • Professional Development
    • Virtual Events
    • Chronicle Store
    • Chronicle Intelligence
    • Find a Job
    • Post a Job
    Explore Content
    • Latest News
    • Newsletters
    • Letters
    • Free Reports and Guides
    • Professional Development
    • Virtual Events
    • Chronicle Store
    • Chronicle Intelligence
    • Find a Job
    • Post a Job
  • Know The Chronicle
    • About Us
    • Write for Us
    • Work at The Chronicle
    • Our Reporting Process
    • Advertise With Us
    • Brand Studio
    • DEI Commitment Statement
    • Accessibility Statement
    Know The Chronicle
    • About Us
    • Write for Us
    • Work at The Chronicle
    • Our Reporting Process
    • Advertise With Us
    • Brand Studio
    • DEI Commitment Statement
    • Accessibility Statement
  • Account and Access
    • Manage Your Account
    • Manage Newsletters
    • Individual Subscriptions
    • Institutional Subscriptions
    • Subscription & Account FAQ
    Account and Access
    • Manage Your Account
    • Manage Newsletters
    • Individual Subscriptions
    • Institutional Subscriptions
    • Subscription & Account FAQ
  • Get Support
    • Contact Us
    • Reprints & Permissions
    • User Agreement
    • Terms and Conditions
    • Privacy Policy
    • California Privacy Policy
    • Do Not Sell My Personal Information
    Get Support
    • Contact Us
    • Reprints & Permissions
    • User Agreement
    • Terms and Conditions
    • Privacy Policy
    • California Privacy Policy
    • Do Not Sell My Personal Information
1255 23rd Street, N.W. Washington, D.C. 20037
© 2023 The Chronicle of Higher Education
  • twitter
  • instagram
  • youtube
  • facebook
  • linkedin